| scholarly article | Q13442814 |
| P50 | author | Christele Desbois-Mouthon | Q58392320 |
| Colette Rey | Q127464857 | ||
| P2093 | author name string | Chantal Housset | |
| Laetitia Fartoux | |||
| Marie-José Blivet-Van Eggelpoël | |||
| Olivier Rosmorduc | |||
| Véronique Barbu | |||
| Lynda Aoudjehane | |||
| Sabrina Priam | |||
| Hamza Chettouh | |||
| P433 | issue | 1 | |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P304 | page(s) | 108-115 | |
| P577 | publication date | 2012-03-10 | |
| P1433 | published in | Journal of Hepatology | Q15724402 |
| P1476 | title | Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells | |
| P478 | volume | 57 |
| Q38612171 | A miR-7/GAS6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma. |
| Q31119684 | Actionable gene expression-based patient stratification for molecular targeted therapy in hepatocellular carcinoma |
| Q36675015 | Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence |
| Q38870684 | Amphiregulin impairs apoptosis-stimulating protein 2 of p53 overexpression-induced apoptosis in hepatoma cells |
| Q53251841 | An antibody to amphiregulin, an abundant growth factor in patients' fluids, inhibits ovarian tumors. |
| Q28538126 | BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib |
| Q38450711 | Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility. |
| Q37708002 | Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age. |
| Q38913419 | Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling |
| Q33779122 | Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy |
| Q34958488 | Decreased expression of hepatocyte nuclear factor 4α (Hnf4α)/microRNA-122 (miR-122) axis in hepatitis B virus-associated hepatocellular carcinoma enhances potential oncogenic GALNT10 protein activity |
| Q41667581 | Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways |
| Q94550269 | Differential effectiveness of tyrosine kinase inhibitors in 2D/3D culture according to cell differentiation, p53 status and mitochondrial respiration in liver cancer cells |
| Q26771265 | EGFR Signaling in Liver Diseases |
| Q35975438 | Epidermal Growth Factor Receptor-Dependent Mutual Amplification between Netrin-1 and the Hepatitis C Virus. |
| Q33863710 | Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma |
| Q33412612 | Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma |
| Q35182909 | Expression and function analysis of mitotic checkpoint genes identifies TTK as a potential therapeutic target for human hepatocellular carcinoma |
| Q90730649 | Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC |
| Q36729450 | HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3. |
| Q90448494 | HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant |
| Q38777310 | HDAC6-mediated EGFR stabilization and activation restrict cell response to sorafenib in non-small cell lung cancer cells |
| Q47910739 | Heat stress induced, ligand-independent MET and EGFR signalling in hepatocellular carcinoma. |
| Q44659249 | Hepatocellular carcinoma and sorafenib: too many resistance mechanisms? |
| Q39307416 | Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists |
| Q39499017 | Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin. |
| Q37244398 | Indole-3- carbinol enhances sorafenib cytotoxicity in hepatocellular carcinoma cells: A mechanistic study |
| Q90395716 | Inhibition of Cyclin-Dependent Kinase 5: A Strategy to Improve Sorafenib Response in Hepatocellular Carcinoma Therapy |
| Q91597640 | Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma |
| Q112717744 | LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation |
| Q92306001 | M2 macrophages mediate sorafenib resistance by secreting HGF in a feed-forward manner in hepatocellular carcinoma |
| Q37049104 | Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma |
| Q35781321 | MiR-34a suppresses amphiregulin and tumor metastatic potential of head and neck squamous cell carcinoma (HNSCC) |
| Q38610677 | Modulation of sensitivity and resistance to multikinase inhibitors by microenvironmental platelet factors in HCC. |
| Q87347005 | NORE1A sensitises cancer cells to sorafenib-induced apoptosis and indicates hepatocellular carcinoma prognosis |
| Q92344153 | New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma |
| Q33759933 | New knowledge of the mechanisms of sorafenib resistance in liver cancer |
| Q38972744 | Novel celastrol derivatives inhibit the growth of hepatocellular carcinoma patient-derived xenografts |
| Q34438331 | Oncolytic immunotherapy using recombinant vaccinia virus GLV-1h68 kills sorafenib-resistant hepatocellular carcinoma efficiently |
| Q28284012 | Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma |
| Q92705174 | Peglated-H1/pHGFK1 nanoparticles enhance anti-tumor effects of sorafenib by inhibition of drug-induced autophagy and stemness in renal cell carcinoma |
| Q48368428 | Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Putative Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry (MRM-MS). |
| Q90589318 | Quantitative phosphoproteomic analysis identifies the potential therapeutic target EphA2 for overcoming sorafenib resistance in hepatocellular carcinoma cells |
| Q28383116 | RNAi screening with shRNAs against histone methylation-related genes reveals determinants of sorafenib sensitivity in hepatocellular carcinoma cells |
| Q53688760 | Recapitulation of pharmacogenomic data reveals that invalidation of SULF2 enhance sorafenib susceptibility in liver cancer. |
| Q28484499 | Regulation of amphiregulin gene expression by β-catenin signaling in human hepatocellular carcinoma cells: a novel crosstalk between FGF19 and the EGFR system |
| Q34728237 | Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out. |
| Q64998595 | Role of microRNAs in the development of hepatocellular carcinoma and drug resistance. |
| Q24619987 | Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update |
| Q57475140 | Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinoma |
| Q58693837 | Silencing the expression of copine-III enhances the sensitivity of hepatocellular carcinoma cells to the molecular targeted agent sorafenib |
| Q37031712 | Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives |
| Q39140861 | Sorafenib sensitizes hepatocellular carcinoma cell to cisplatin via suppression of Wnt/β-catenin signaling |
| Q38635603 | Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma |
| Q92194916 | TMPRSS4 Drives Angiogenesis in Hepatocellular Carcinoma by Promoting HB-EGF Expression and Proteolytic Cleavage |
| Q39270408 | Targeting of growth factors in the treatment of hepatocellular carcinoma: The potentials of polysaccharides |
| Q44456046 | The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy |
| Q38169563 | The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesis |
| Q35045419 | The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance |
| Q38674137 | The Therapeutic Targeting of HGF/c-Met Signaling in Hepatocellular Carcinoma: Alternative Approaches |
| Q46215513 | The coffee diterpene kahweol enhances sensitivity to sorafenib in human renal carcinoma Caki cells through down-regulation of Mcl-1 and c-FLIP expression |
| Q41141854 | The long noncoding RNA lnc-EGFR stimulates T-regulatory cells differentiation thus promoting hepatocellular carcinoma immune evasion. |
| Q36088178 | The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III |
| Q64902442 | Transcriptome analysis identifies metallothionein as biomarkers to predict recurrence in hepatocellular cacinoma. |
| Q38812372 | Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma |
| Q38969661 | Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma. |
| Q37493227 | YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma |
| Q42165937 | β-PDGF receptor expressed by hepatic stellate cells regulates fibrosis in murine liver injury, but not carcinogenesis |
Search more.